Ridinilazole

Generic Name
Ridinilazole
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H16N6
CAS Number
308362-25-6
Unique Ingredient Identifier
06DX01190R
Background

Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

First Posted Date
2021-03-17
Last Posted Date
2023-08-21
Lead Sponsor
Summit Therapeutics
Target Recruit Count
2
Registration Number
NCT04802837
Locations
🇺🇸

Stony Brook University Medical Center, Stony Brook, New York, United States

🇺🇸

Continental Clinical Research, Miami, Florida, United States

🇺🇸

Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States

and more 15 locations

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

First Posted Date
2018-07-23
Last Posted Date
2023-03-03
Lead Sponsor
Summit Therapeutics
Target Recruit Count
759
Registration Number
NCT03595553
Locations
🇧🇬

DCC1-Sliven Ltd., Sliven, Bulgaria

🇬🇷

''Tzaneio'' General Hospital of Piraeus, Piraeus, Greece

🇭🇺

Dr. Kenessey Albert Kórház Rendelőintézet, Tüdőgyógyászati Aktív Osztály, Balassagyarmat, Hungary

and more 146 locations

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

First Posted Date
2016-05-26
Last Posted Date
2017-10-12
Lead Sponsor
Summit Therapeutics
Target Recruit Count
27
Registration Number
NCT02784002
Locations
🇺🇸

Laguna Hills, Laguna Hills, California, United States

🇺🇸

Ventura, Ventura, California, United States

🇨🇿

Pardubice, Pardubice, Czechia

and more 13 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy